Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseasesse

Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Marea Therapeutics Enrolls First Participant in Phase 1 Clinical Study Evaluating MAR002 for Acromegaly

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

ARTBIO Appoints Four New Board Members, Co-Founder Transitions to Technical Advisory Board Role

Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update

Flare Therapeutics Announces Initiation of Phase 1B Study of FX-909 for Treatment of Metastatic Urothelial Cancer

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Marea Therapeutics Enrolls First Patient in Phase 2b TYDAL-TIMI 78 Clinical Study Evaluating MAR001 in Adults at Risk of ASCVD

ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha Radioligand Therapies and Expand Manufacturing and Supply Chain Infrastructure

MOMA Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial for MOMA-341,a Highly Potent and Selective Werner Helicase Inhibitor

Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress

Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025

Marea Therapeutics Appoints Shishir Gadam, Ph.D., as Chief Technical Officer

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

Marea Therapeutics Announces Oral Presentation Related to Acromegaly Program at ENDO 2025

Candid Therapeutics Advances Portfolio of Novel T-Cell Engagers into Five Autoimmune Diseases for Clinical Evaluation

Casma Therapeutics Nominates CSM-101 as a Development Candidate for the Treatment of Rare and Common Forms of Parkinson’s Disease

Septerna to Present at Jefferies Global Healthcare Conference

Flare Therapeutics to Participate in Jefferies Global Healthcare Conference

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

Marea Therapeutics Appoints Charmi Turner as Senior Vice President, People & Culture

ARTBIO Expands Radiopharmaceutical R&D Capabilities with Move to Oslo Science Park

Marea Therapeutics Announces Publication in The Lancet of Positive Data from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Synnovation Therapeutics Announces the Appointment of Rafael G. Amado, M.D., to Its Board of Directors

Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Clasp Therapeutics Doses First Patient in Phase 1 Clinical Trial with a First-in-Class T-Cell Engager Designed to Target Cancer Cells with Absolute Specificity

Seaport Therapeutics Presents New Preclinical Data on SPT-320 (Glyph Agomelatine) at the Society of Biological Psychiatry (SOBP) Annual Meeting

MOMA Therapeutics to Present Multiple Posters at the American Association for Cancer Research Annual Meeting 2025

Merida Biosciences Launches with $121M to Create Therapeutics for Multiple Autoimmune and Allergic Diseases
 

MOMA Therapeutics Appoints Susan Pandya, M.D., to Board of Directors and Expands Management Team
 

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
 

Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

CARGO Therapeutics Provides Corporate Update

Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

Synnovation Therapeutics Announces Second Program to Enter the Clinic: First Patient Dosed in Phase I Trial with SNV4818, a Potential Best-In-Class Pan-Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors

Seaport Therapeutics Presents New Meta-Analysis Examining Correlations Between Clinical Trial Design Factors and Placebo Response in Major Depressive Disorder Studies

Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis